Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021
ENHANCE Phase 3 program on track to report top-line data in 2022
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended September 30, 2021, and provides a corporate update.
